Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

References

• Rubenstein J, Ferreri AJM, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49: 43–51.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Pfeiffer RM, Besson C. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol. 2016;174:417–424.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Treseler P, O'Brien JM. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am. 2005;19:705–717.
   PubMed Web of Science ®Google Scholar
• Jakobsen LH, Bøgsted M, Brown P. d N, et al. minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. J Clin Oncol. 2017;35:778–784.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512–1520.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–e227.
   PubMed Web of Science ®Google Scholar
• Pulczynski EJ, Kuittinen O, Erlanson M, et al. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group. Haematologica. 2005;100:534–540.
   Google Scholar
• Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066–1073.
   PubMed Web of Science ®Google Scholar
• Shi Q, Schmitz N, Ou FS, et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol. 2018;36:2593–2602.
   PubMed Web of Science ®Google Scholar
• Arboe B, El-Galaly TC, Clausen MR, et al. The Danish National Lymphoma Registry: coverage and data quality. PLoS One. 2016;11:e0157999.
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Scott DW, Slack GW, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28:2489–2495.
   PubMed Web of Science ®Google Scholar
• Thorsgaard M, von Oettingen G, EL-Galaly TC, et al. Retnings Linjer for Diagnostik Og Behandling Af Primaere CNS Lymfomer Og CNS Lymfomer Hos Immun Kompetente Patienter. Arhus, Denmark. 2015. Available from: http://www.lymphoma.dk/wp-content/uploads/2016/11/Retningslinjer_CNS_lymfomer_ver_2015_030916.pdf
   Google Scholar
• Kansara R, Shenkier TN, Connors JM, et al. Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol. 2015;90:1149–1154.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346.
   PubMedGoogle Scholar
• Royston P, Parmar M. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statist Med. 2011;30:2409–2421.
   PubMed Web of Science ®Google Scholar
• Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101–121.
   PubMedGoogle Scholar
• University of California Berkeley and Max Planck Institute for Demographic Research. Human Mortality Database; [data downloaded on 2016 Dec 01]. Available from: www.mortality.org
   Google Scholar
• Statistics Canada. Table 13-10-0114-01 Life expectancy and other elements of the life table, Canada, all provinces except Prince Edward Island. Avaialble from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310011401
   Google Scholar
• Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York (NY): Springer-Verlag; 2005.
   Google Scholar
• Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol. 1998;16:1561–1567.
   PubMed Web of Science ®Google Scholar
• Ferreri A. How I treat primary CNS lymphoma. Blood. 2011;118:510–522.
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Siebert R, Deckert M. Primary lymphoma of the central nervous system: just DLBCL or not? Blood. 2009;113:7–10.
   PubMed Web of Science ®Google Scholar
• Villa D, Slack GW, Al-Moosawi M, et al. Molecular features of primary central nervous system lymphoma in a large tissue microarray. Blood. 2018;132:348–348.
   PubMed Web of Science ®Google Scholar
• Eloranta S, Brånvall E, Celsing F, et al. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013. Eur J Haematol. 2018;100:61–68.
   PubMed Web of Science ®Google Scholar
• Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105:1414–1418.
   PubMed Web of Science ®Google Scholar
• Tian L, Fu H, Ruberg SJ, et al. Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations. Biom. 2018;74:694–702.
   Google Scholar
• Ferreri AJM, Blay JY, Reni M, et al. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. J Clin Oncol. 2003;21:266–272.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5715.
   PubMed Web of Science ®Google Scholar